Bradley Merrill Thompson Quoted in “FDA Delays Rule Affecting Off-Label Drug, Device Promotion”Bloomberg BNA Medical Devices Law & Industry Report February 6, 2017
Bradley Merrill Thompson, a Member of the Firm in the Health Care and Life Sciences practice, in the firm’s Washington, DC, office, was quoted in Bloomberg BNA Medical Devices Law & Industry Report, in “FDA Delays Rule Affecting Off-Label Drug, Device Promotion,” by Bronwyn Mixter. (Read the full version – subscription required.)
Following is an excerpt:
Bradley Merrill Thompson, a Washington-based attorney with Epstein Becker & Green PC, told Bloomberg BNA in a Feb. 6 e-mail he is disappointed the changes that affect the off-label promotion of medical devices will be delayed. “But hopefully this will just be a delay while they are reviewed under the new administration. I'm hoping that ultimately the new administration goes forward with them,” he said. Thompson counsels medical device, drug and combination product companies on a wide range of FDA issues.